<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053820</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000269480</org_study_id>
    <secondary_id>MRC-RE04</secondary_id>
    <secondary_id>EORTC-30012</secondary_id>
    <secondary_id>EU-20231</secondary_id>
    <secondary_id>ISRCTN46518965</secondary_id>
    <nct_id>NCT00053820</nct_id>
  </id_info>
  <brief_title>Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer</brief_title>
  <official_title>A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon alfa may interfere with the growth of tumor cells. Interleukin-2 may
      stimulate a person's white blood cells to kill tumor cells. Drugs used in chemotherapy use
      different ways to stop tumor cells from dividing so they stop growing or die. Combining
      interferon alfa with interleukin-2 and fluorouracil may kill more tumor cells. It is not yet
      known whether interferon alfa is more effective with or without interleukin-2 and
      fluorouracil in treating metastatic kidney cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa combined
      with interleukin-2 and fluorouracil to that of interferon alfa alone in treating patients who
      have advanced metastatic kidney cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare progression-free and overall survival of patients with advanced metastatic renal
           carcinoma treated with interferon alfa with or without interleukin-2 and fluorouracil.

        -  Compare the toxicity of these regimens in these patients.

        -  Assess the quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of
      2 treatment arms.

        -  Arm I (Interferon alfa monotherapy): Patients receive interferon alfa subcutaneously
           (SC) on days 1, 3, and 5. Treatment continues weekly for at least 9 weeks in the absence
           of disease progression or unacceptable toxicity.

        -  Arm II (Interferon alfa, interleukin-2, and fluorouracil combination therapy): Patients
           receive interferon alfa SC on day 1 of weeks 1 and 4 and days 1, 3, and 5 of weeks 2, 3,
           5, 6, 7, and 8. Patients also receive interleukin-2 SC twice daily on days 3-5 of weeks
           1 and 4 and once daily on days 1, 3, and 5 of weeks 2 and 3. Patients then receive
           fluorouracil IV on day 1 of weeks 5-8. Treatment repeats every 10 weeks for up to 2
           courses in the absence of disease progression or unacceptable toxicity.

      Quality of life is assessed at baseline, at 9, 19, and 26 weeks, and then at 8 months.

      Patients are followed at 8, 10, and 12 months, every 4 months for 1 year, and then every 6
      months thereafter.

      PROJECTED ACCRUAL: A total of 670 patients (335 per treatment arm) will be accrued for this
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression as measured by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of toxicity levels (Grade III and IV)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of quality of life before, during, after completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the treatment regimens on health economics</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">670</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed renal cell carcinoma

               -  Advanced metastatic disease that requires treatment

          -  Measurable disease (single bone lesions not included)

          -  No brain metastasis

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 81

        Performance status

          -  WHO 0-1

        Life expectancy

          -  More than 12 weeks

        Hematopoietic

          -  WBC greater than 3,000/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  Hemoglobin greater than 10 g/dL

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Cardiovascular

          -  No myocardial infarction within the past 6 months

          -  No unstable angina pectoris

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for at least 6 months
             after study participation

          -  No other concurrent disease or prior malignancy that would preclude study treatments
             or comparisons

          -  No concurrent active infection requiring antibiotics

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior biologic therapy

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  No prior endocrine therapy

          -  No concurrent corticosteroids

        Radiotherapy

          -  At least 4 weeks since prior radiotherapy

        Surgery

          -  Prior resection of the primary tumor recommended but not required

          -  No prior major organ allografts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin E. Gore, MD</last_name>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter F.A. Mulders, MD, PhD</last_name>
    <affiliation>Universitair Medisch Centrum St. Radboud - Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>B-9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis der Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>D-34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Rotterdam at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute - Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Slovakia</country>
  </location_countries>
  <results_reference>
    <citation>Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet. 2010 Feb 20;375(9715):641-8. doi: 10.1016/S0140-6736(09)61921-8. Epub 2010 Feb 10.</citation>
    <PMID>20153039</PMID>
  </results_reference>
  <results_reference>
    <citation>Gore ME: Interferon-Î± (IFN), interleukin-2 (IL2) and 5-fluorouracil (5FU) vs IFN alone in patients with metastatic renal cell carcinoma (mRCC): results of the randomised MRC/EORTC RE04 trial. [Abstract] J Clin Oncol 26 (Suppl 15): A-5039, 2008.</citation>
  </results_reference>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

